NMD-GPS (Genomic and Proteomic Signatures as a GPS in Neuromuscular Diseases) is a multidisciplinary German/European project funded with 2,9 million Euros for a total period of three years (by the European Regional Development Fund; ERDF) and applying proteogenomics to improve NMD diagnostics by replacing immunology-based analyses with proteomics.

In this project, NMD-causative-proteins are quantified by targeted proteomics, while untargeted proteomics on the same protein extracts then aims to map pathophysiological cascades across diseases, including both genetic and acquired NMDs. Intersection of proteogenomics and clinical data via machine learning will enable identification of molecular causes in an antibody-independent fashion as well as pinpointing significant protein co-regulations.